Loading
Volitionrx Ltd Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Henshall Mickie, was filed 19 Sept 2023.
Volitionrx Ltd: what insiders have been doing
This page follows insider dealings at Volitionrx Ltd as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. From 22 October 2025 to 22 October 2026, the disclosure feed for Volitionrx Ltd logged 27 filings by 16 insiders.
The filings describe grants, exercises and other transfers rather than trades on the open market. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
No insider has bought Volitionrx Ltd shares on the open market in the past twelve months. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. For comparison, the SEC allows two business days to file a Form 4.
With 27 filings in twelve months, the company is quieter than the median of 41 filings across the 2,023 companies we follow on the same exchange. Since 2016, the database holds 51 purchases and 14 sales by insiders of the company. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 1.7 m USD and net income at -23.4 m USD.
Elsewhere in the same sector, our signals recently picked up insider purchases at Xenon Pharmaceuticals Inc. and Vivos Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
399
Thresholds
n/a
Buy Volume
€2M
51 ops. · all time
Sell Volume
€701,889
14 ops. · all time
Since the insiders bought
- -39.6%Entry US$21.20 · Close at T+365 US$12.80
- -46.6%Entry US$26.20 · Close at T+365 US$14.00
- -43.2%Entry US$25.00 · Close at T+365 US$14.20
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.18
Analyst consensus
5 analysts1.60/5
US$2.00Target US$13.62(+7464%)US$24.00
Income statement
RevenueUS$1.7M
EBITDA-US$19.8M-1146% margin
Net income-US$23.4M-1352.2% margin
Valuation
PER (forward)-0.2x
Beta1.17
Balance sheet & cash
Market capUS$5.4M
Total debtUS$11.5M
Free Cash Flow-US$19.8M
Profitability & ownership
ROA-142.9%
% insiders3.3%
% institutions10.8%
Last declaration on 27 February 2026
Declarations399 total
149,000 shares0Common StockSEC:0001477932-26-001105:0
178,000 shares0Common StockSEC:0001477932-26-001098:0
178,000 shares0Common StockSEC:0001477932-26-001104:0
173,000 shares0Common StockSEC:0001477932-26-001097:0
486,000 shares0Common StockSEC:0001477932-26-001103:0
142,000 shares0Common StockSEC:0001477932-26-001102:0
178,000 shares0Common StockSEC:0001477932-26-001095:0
149,000 shares0Common StockSEC:0001477932-26-001096:0
187,000 shares0Common StockSEC:0001477932-26-001099:0
119,000 shares0Common StockSEC:0001477932-26-001100:0
202,000 shares0Common StockSEC:0001477932-26-001101:0
74,700 shares0Common StockSEC:0001477932-26-000370:0
12,000 shares0Common StockSEC:0001477932-26-000369:0
12,000 shares0Common StockSEC:0001477932-26-000373:0
12,000 shares0Common StockSEC:0001477932-26-000360:0
44,700 shares0Common StockSEC:0001477932-26-000361:0
90,000 shares0Common StockSEC:0001477932-26-000368:0
33,900 shares0Common StockSEC:0001477932-26-000367:0
12,000 shares0Common StockSEC:0001477932-26-000359:0
12,000 shares0Common StockSEC:0001477932-26-000365:0
42,000 shares0Common StockSEC:0001477932-26-000358:0
28,200 shares0Common StockSEC:0001477932-26-000363:0
12,000 shares0Common StockSEC:0001477932-26-000372:0
35,400 shares0Common StockSEC:0001477932-26-000362:0
53,400 shares0Common StockSEC:0001477932-26-000364:0
25 of 399 declarations
About Volitionrx Ltd
VolitionRx Ltd (ticker: VNRX) is a U.S.-listed healthcare company trading on NYSE American in the United States, focused on epigenetics-based diagnostics. Founded in 2010, the company began with a small laboratory footprint at the University of Namur in Belgium and has since evolved into an international organization with a purpose-built manufacturing facility in Belgium, an innovation laboratory in the U.S., and offices in California, London, Singapore, and Henderson, Nevada. Its corporate presence and investor relations base are in the United States, while research and development remain centered in Belgium. ([volition.com](https://volition.com/our-company/?utm_source=openai))
Volition’s business model is built around its proprietary Nucleosomics™ technology and its Nu.Q® biomarker platform. The company is developing and commercializing blood-based tests intended to help detect, monitor, and potentially stratify a range of diseases, including several cancers and conditions associated with NETosis, such as sepsis. A meaningful aspect of the portfolio is the extension into veterinary diagnostics, particularly the Nu.Q® Vet franchise, including feline cancer testing. This gives Volition exposure to both human and animal health markets, although it remains largely in a development and early commercialization phase rather than a fully scaled diagnostics supplier. ([ir.volition.com](https://ir.volition.com/))
Read moreShow less
From a competitive standpoint, Volition operates in a highly specialized niche at the intersection of diagnostic testing, oncology, inflammatory disease detection, and epigenetic biomarkers. Its differentiation lies in the scientific promise of Nu.Q® and the breadth of possible use cases across cancer screening, disease monitoring, trauma, sepsis, and veterinary oncology. That said, the company faces major execution hurdles typical of emerging diagnostics names: regulatory approval, reimbursement adoption, clinical validation, commercialization scale-up, and competition from much larger global diagnostic companies with greater capital resources. ([ir.volition.com](https://ir.volition.com/news-events/press-releases/detail/870/volitionrx-limited-announces-the-preparation-of-reimbursement-submission-for-its-nu-q-cancer-assays?utm_source=openai))
Recent developments suggest a company pushing to convert clinical momentum into commercial traction. In 2026, Volition reported first-quarter results and a business update, advanced reimbursement preparation in France for its Nu.Q® Cancer assays, announced breakthrough finger-prick detection of nucleosomes for sepsis applications, released Mayo Clinic-related trauma data, and submitted a manuscript for its Nu.Q® Vet Feline cancer test. The company also secured funding in January 2026 and later obtained EUR 2.0 million of non-dilutive funding from regional government agencies in Belgium, reinforcing its reliance on a mixed financing approach to support clinical studies, product commercialization, and general corporate needs. ([ir.volition.com](https://ir.volition.com/news-events/press-releases/detail/888/volitionrx-limited-announces-first-quarter-2026-financial-results-and-business-update?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
